Sarepta Therapeutics, Inc. or Alkermes plc: Who Leads in Yearly Revenue?

A Decade of Revenue Growth: Alkermes plc vs. Sarepta Therapeutics, Inc.

In the competitive landscape of biotechnology, revenue growth is a key indicator of success. Over the past decade, Alkermes plc and Sarepta Therapeutics, Inc. have been at the forefront of innovation, each carving out a niche in the industry. From 2014 to 2023, Alkermes plc consistently outperformed Sarepta in terms of revenue, with a notable peak in 2023, where it reached approximately $1.66 billion, marking a 168% increase from its 2014 revenue. Meanwhile, Sarepta Therapeutics, Inc. demonstrated impressive growth, especially from 2017 onwards, achieving a remarkable 12,600% increase in revenue by 2023, reaching around $1.24 billion. This growth trajectory highlights Sarepta's rapid expansion and increasing market presence. As both companies continue to innovate, the coming years will be crucial in determining who will lead the biotech revenue race.